Literature DB >> 17976620

Retinopathy in patients with sickle cell trait.

Sherrol A Reynolds1, Eulogio Besada, Christine Winter-Corella.   

Abstract

BACKGROUND: Sickle hemoglobinopathies are among the most prevalent genetic disorders in the United States. Sickle cell trait (hemoglobin AS) is the most common genotype and has traditionally been considered a benign condition. Systemic and ocular complications are seen infrequently in patients with sickle cell trait. In the presence of concomitant systemic diseases or trauma, however, marked retinopathy can occur. The presence of retinopathy in patients with sickle cell trait necessitates a comprehensive medical workup, including serologic testing to rule out systemic conditions. CASE REPORTS: Two cases are presented. The patient in case 1 is a 44-year-old black man with a positive history of sickle cell trait and uncontrolled hypertension. Best-corrected visual acuities (BCVAs) were 20/20 in the right eye (O.D.) and the left eye (O.S.). Retinal evaluation found vitreo-retinal fibrotic scaffolding and "sea-fan" neovascularization. The patient in case 2 is a 45-year-old black woman who presented after a stroke 1-month prior. Her medical history was positive for hypertension, hypercholesterolemia, a recently diagnosed aneurismal dilation of the ascending thoracic aorta, and sickle cell trait. BCVAs were 20/20 O.D., and 20/20 O.S. A single dot hemorrhage was evident O.D., and an inferior-temporal branch retinal artery occlusion with an adjacent area of sea-fan neovascularization was observed O.S.
CONCLUSION: Sickle cell disease remains a major public health concern because of its associated significant morbidity and mortality. Sickle cell trait is considered benign in a healthy patient. However, under conditions of stress, concomitant systemic diseases, or trauma leading to hypoxia, sickle cell trait can become a pathologic risk factor.

Entities:  

Mesh:

Year:  2007        PMID: 17976620     DOI: 10.1016/j.optm.2007.04.100

Source DB:  PubMed          Journal:  Optometry        ISSN: 1558-1527


  8 in total

1.  Hemoglobin AC retinopathy managed with vitrectomy and adjunctive bevacizumab.

Authors:  R Pokroy; U R Desai
Journal:  Eye (Lond)       Date:  2011-08-05       Impact factor: 3.775

2.  Choroidal vascular occlusion in a young male patient with sickle cell trait.

Authors:  Maria Kotoula; Eleni Papageorgiou; Foteini Xanthou; Sotirios Kalampalikis; Sofia Androudi; Evangelia E Tsironi
Journal:  Int J Ophthalmol       Date:  2018-03-18       Impact factor: 1.779

3.  Retinal arterial occlusions in the young: systemic associations in Indian population.

Authors:  Dhanashree Ratra; Maneesh Dhupper
Journal:  Indian J Ophthalmol       Date:  2012 Mar-Apr       Impact factor: 1.848

Review 4.  Sickle cell retinopathy: improving care with a multidisciplinary approach.

Authors:  Farid Menaa; Barkat Ali Khan; Bushra Uzair; Abder Menaa
Journal:  J Multidiscip Healthc       Date:  2017-08-30

5.  A retinopathy in young patient with co-inheritance of heterozygous alpha + -thalassemia and sickle trait: a case report.

Authors:  Zohra Ouzzif; Aissam El Maataoui; Zeinab Traore; Asmae Biaz; Samira El Machtani; Abdellah Dami; Sanae Bouhsain; Nezha Messaoudi; Fatiha Benchrifa
Journal:  BMC Ophthalmol       Date:  2017-01-18       Impact factor: 2.209

6.  Sickle Cell Trait Presenting as Unilateral Proliferative Retinopathy and Macular Thinning in a Pregnant Woman.

Authors:  Sepideh Ghods; Elias Khalili Pour; Hooshang Faghihi; Golnaz Gharehbaghi; Ahmad Mirshahi; Fariba Ghassemi; Bahman Inanloo; Hamid Riazi-Esfahani
Journal:  Case Rep Ophthalmol Med       Date:  2021-12-11

7.  Retinal and choroidal thickness in pediatric patients with sickle cell disease: a cross-sectional cohort study.

Authors:  Juliana Prazeres; Luiz Filipe Lucatto; Adriano Ferreira; Nilva Moraes; Josefina A P Braga; Luiz H Lima; Caio Regatieri; Maurício Maia
Journal:  Int J Retina Vitreous       Date:  2022-03-04

8.  Retinopathy in Egyptian patients with sickle cell disease: A cross-sectional study.

Authors:  Tamer Hassan; Mohamed Badr; Diana Hanna; Mohamed Arafa; Ahmed Elhewala; Sherief Dabour; Saad Shehata; Doaa Abdel Rahman
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.